Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon

Fineline Cube Jun 1, 2026
Company Deals

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

Fineline Cube Jun 1, 2026
Company Deals

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations

Fineline Cube Jun 1, 2026
Company Deals

Sihuan Pharmaceutical and dProtein Biotechnology Form AI-Powered Medical Aesthetics Joint Venture

Fineline Cube May 29, 2026
Company Deals Drug

Salvectors Receives NMPA Clinical Approval for YB1-X7, World’s First Oncolytic Salmonella Therapy for Advanced Solid Tumors

Fineline Cube May 29, 2026
Policy / Regulatory

NMPA Opens 2026 National Reimbursement Drug List Application Window with Revised Eligibility Criteria and Price Controls

Fineline Cube Jun 1, 2026
Company Drug

D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026

Fineline Cube Jun 1, 2026
Company Drug

Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026

Fineline Cube Jun 1, 2026
Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003

Fineline Cube Dec 5, 2022

China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...

Company Deals

Lavamed Secures USD 40M in Angel and Series A Financing Rounds

Fineline Cube Dec 5, 2022

Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...

Company Drug

Innovent Biologics Doses First Volunteer in Orismilast Phase I Study

Fineline Cube Dec 5, 2022

China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...

Company Drug

Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study

Fineline Cube Dec 5, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...

Company Deals

Tsingke Biotech Secures RMB 400M Series B Financing for Expansion

Fineline Cube Dec 5, 2022

Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...

Company Deals

China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia

Fineline Cube Dec 5, 2022

China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...

Company Deals

SAFE Raises RMB 500M in Series D Financing to Expand CRO Services

Fineline Cube Dec 5, 2022

Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...

Company Medical Device

Peijia Medical Enrolls First Patient in GeminiOne TEER System Study

Fineline Cube Dec 5, 2022

China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study...

Company Drug

NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer

Fineline Cube Dec 2, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...

Company Deals

Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...

Company Drug

Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials

Fineline Cube Dec 2, 2022

China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...

Company Deals

Eli Lilly Ends License for Innovent’s Tyvyt Outside China

Fineline Cube Dec 2, 2022

Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...

Company Deals

Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China

Fineline Cube Dec 2, 2022

Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...

Company Deals Digital

Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine

Fineline Cube Dec 2, 2022

China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...

Company Deals

Pediatrix Therapeutics Licenses Tris Pharma’s ADHD Portfolio for Greater China

Fineline Cube Dec 2, 2022

China-based Pediatrix Therapeutics announced a licensing agreement with US firm Tris Pharma, Inc., obtaining exclusive...

Policy / Regulatory

Hainan’s New Regulations on Medical Devices in Boao Lecheng to Take Effect in 2023

Fineline Cube Dec 2, 2022

The “Regulations on the Administration of Medical Devices in Boao Lecheng International Medical Tourism Pilot...

Company Drug

Kintor’s KX-826 Reaches Primary Endpoint in Phase II Study for Female AGA

Fineline Cube Dec 2, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced that the Phase II clinical study for its...

Company Medical Device

Sansure Biotech’s Pertussis Detection Kit Approved by NMPA

Fineline Cube Dec 2, 2022

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced that it has obtained medical...

Company Drug

Simcere’s Edaravone, Borneol Sublingual Tablets Reach Phase III Efficacy Endpoint

Fineline Cube Dec 2, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that a Phase III clinical study for...

Digital R&D

AI Model for Early Alzheimer’s Detection Using Retinal Photographs Published

Fineline Cube Dec 2, 2022

A joint Singapore-UK-Hong Kong research team has published details of an AI-based deep learning model...

Posts pagination

1 … 601 602 603 … 675

Recent updates

  • D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026
  • Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026
  • CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026
  • GenFleet’s GFS202A Becomes World’s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026
  • LaNova’s CLDN18.2 ADC LM-302 Shows 15-Month PFS in Gastric Cancer Phase II Data at ASCO 2026
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026

Company Drug

Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026

Company Drug

CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026

Company Drug

GenFleet’s GFS202A Becomes World’s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.